DelveInsight’s, “Discoidin Domain Receptor Antagonists - Pipeline Insight, 2022,” report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Discoidin Domain Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discoidin Domain Receptor Antagonists: Overview
The discoidin domain receptor (DDR) family comprises two distinct members, DDR1 and DDR2, which were initially discovered in the early 1990s and characterized as receptor tyrosine kinases (RTKs) based on the presence of a catalytic kinase domain (KD). Subsequently, collagens were identified as ligands for DDRs, thus establishing the unique characteristic of these receptors among other members of the RTK superfamily. Upon collagen binding, DDRs undergo tyrosine autophosphorylation with distinctive activation kinetics, which elicits genetic and cellular programs that regulate a variety of cell-collagen interactions.
The companies and academics are working to assess challenges and seek opportunities that could influence Discoidin Domain Receptor Antagonists R&D. The therapies under development are focused on novel approaches for Discoidin Domain Receptor Antagonists.
This segment of the Discoidin Domain Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Discoidin Domain Receptor Antagonists Emerging Drugs
Merestinib: Eli Lilly and Company
Merestinib (LY2801653) is an experimental cancer drug in development by Eli Lilly. It is a small molecule inhibitor of MET and several other receptor tyrosine kinases such as MST1R, FLT3, AXL, MERTK, TEK, ROS1, NTRK1/2/3, and DDR1/2.Meristinib is part of a phase II clinical trial for advanced billiary tract cancer.
APL-102: Apollomics
APL-102 is an oral, small molecule multi-tyrosine kinase inhibitor (MTKI) targeting several key oncogenic drivers. APL-102 inhibits several receptor tyrosine kinases (RTKs), including; Angiogenesis via Vascular Endothelial Growth Factor Receptors (VEGFR); Mitogen-Activated Protein Kinases (MAPK) pathway via B-RAF and C-RAF; and Colony stimulating factor 1 receptor (CSF1R). Shown to inhibit several kinases which are aberrantly activated in cancer cells, including VEGFR, MAP4K5, c-RAF and DDR1. APL-102 has demonstrated broad and potent preclinical anti-tumor activity in patient-derived xenograft models of colon, liver, breast, kidney, esophageal and lung cancers. In China, the company received Investigational New Drug (IND) approval, and is conducting a Phase 1 dose escalation and extension study of APL-102 in subjects with solid tumors as a monotherapy.
Further product details are provided in the report……..
This segment of the report provides insights about the different Discoidin Domain Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 4+ key companies which are developing the Discoidin Domain Receptor Antagonists. The companies which have their Discoidin Domain Receptor Antagonists drug candidates in the most advanced stage, i.e. Phase II include, Eli Lilly and Company.
DelveInsight’s report covers around 6+ products under different phases of clinical development like
Discoidin Domain Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Discoidin Domain Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Discoidin Domain Receptor Antagonists drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Discoidin Domain Receptor Antagonists: Overview
Pipeline Therapeutics
Therapeutic Assessment
Discoidin Domain Receptor Antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Merestinib: Eli Lilly and Company
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AVI 4015: Avixgen
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Gutinib 1: KeifeRx
Drug profiles in the detailed report…..
Inactive Products
Discoidin Domain Receptor Antagonists Key Companies
Discoidin Domain Receptor Antagonists Key Products
Discoidin Domain Receptor Antagonists- Unmet Needs
Discoidin Domain Receptor Antagonists- Market Drivers and Barriers
Discoidin Domain Receptor Antagonists- Future Perspectives and Conclusion
Discoidin Domain Receptor Antagonists Analyst Views
Discoidin Domain Receptor Antagonists Key Companies
Appendix
List of Table
Table 1: Total Products for Discoidin Domain Receptor Antagonists
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Discoidin Domain Receptor Antagonists
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Eli Lilly and Company
• APL 102
• KeifeRx
• Avixgen
• Aptose Biosciences
